Ocular Surgery News
Use of a novel anti-platelet-derived growth factor therapy in concert with ranibizumab resulted in a statistically significant improvement in visual outcome vs. ranibizumab monotherapy for the treatment of wet age-related macular degeneration, according to a press release from Ophthotech.